// App-Quantinova.ai

: 30 A Randomized, Controlled, Crossover Study to Assess the Abuse Potential of Lasmiditan

Researchers

Presenter

  • Darren Wilbraham

Principal Investigators

  • Paul H. Berg

  • Max Tsai

  • Emily Liffick

  • Erin G. Doty

  • Li Shen Loo

  • Edward Sellers

Medical Centers

  • Eli Lilly and Company, Indianapolis, IN

  • Department of Pharmacology and Toxicology, Medicine, and Psychiatry, University of Toronto, Toronto, Ontario, Canada

  • DL Global Partners Inc., Toronto, Ontario, Canada,

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Alprazolam

  • lasmiditan

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Cross Over

  • Double Blind/Blinded

  • Non Inferiority

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved